GlobeNewswire·Nov 4, 2025, 7:09 AM ET

Relmada Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Relmada Therapeutics priced an underwritten offering of 40,142,000 common shares & pre-funded warrants for up to 5,315,000 shares.
Common stock was sold at $2.20 per share, while pre-funded warrants were sold at $2.199 per warrant.
Gross proceeds before expenses are expected to be approximately $100 million.
The offering is expected to close on November 5, 2025, subject to customary conditions.
Investors included Janus Henderson Investors, Ferring Ventures SA, Squadron Capital Management, Marshall Wace, Spruce Street Capital, OrbiMed, Columbia Threadneedle Investments, & Driehaus Capital Management.
Jefferies & Leerink Partners served as joint book-running managers, with Mizuho acting as book-runner.
Net proceeds will fund working capital, general corporate purposes, clinical studies, regulatory compliance, product development, licensing, & potential acquisitions.
The securities were offered pursuant to a shelf registration statement on Form S-3 declared effective by the SEC on September 12, 2024.
A final prospectus supplement describing the offering terms will be filed with the SEC.